Earnings Call Summary | ElectroCore(ECOR.US) Q1 2024 Earnings Conference
Earnings Call Summary | ElectroCore(ECOR.US) Q1 2024 Earnings Conference
The following is a summary of the ElectroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript:
以下是ElectroCore, Inc.（ECOR）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
ElectroCore reported a sixth consecutive record revenue quarter of $5.4 million for Q1 2024, a 96% increase year-over-year.
The company's five-year compound annual growth rate exceeded 67% from Q1 2019 through Q1 2024.
Gross margin was reported at 84% for the period.
Sales in the VA channel saw a significant increase, growing 127% to $3.9 million in Q1 2024.
Both Truvega and TAC-STIM brands saw increased sales year-on-year.
ElectroCore報告稱，2024年第一季度收入連續第六個季度創下創紀錄的540萬美元，同比增長96％。
從2019年第一季度到2024年第一季度，該公司的五年複合年增長率超過67％。
據報道，該期間的毛利率爲84％。
弗吉尼亞州渠道的銷售額大幅增長，2024年第一季度增長了127％，達到390萬美元。
Truvega和TAC-STIM品牌的銷售額均同比增長。
Business Progress:
業務進展：
Last year, ElectroCore successfully launched two new non-prescription product lines: Truvega and TAC-STIM, both exceeding initial sales expectations.
The expansion of the company's presence in the VA Hospital System proved successful, with an increase in the number of VA facilities purchasing ElectroCore's products.
Strategic partnerships with Joerns Healthcare and Lovell Government Services are expected to bring increased revenue growth in H2 2024.
The company anticipates launching a second-generation product 'TAC-STIM Black' and continues to invest in several clinical trials.
ElectroCore's future plans include prescription gammaCore label extensions, expansion of distribution channels including online, and deeper reach within each VA facility.
去年，ElectroCore成功推出了兩條新的非處方產品系列：Truvega和TAC-STIM，均超過了最初的銷售預期。
事實證明，該公司在弗吉尼亞州醫院系統中的業務擴張是成功的，購買ElectroCore產品的弗吉尼亞州機構數量有所增加。
與Joerns Healthcare和洛弗爾政府服務的戰略合作伙伴關係預計將在2024年下半年帶來收入增長。
該公司預計將推出第二代產品 “TAC-STIM Black”，並繼續投資多項臨床試驗。
ElectroCore的未來計劃包括延長處方藥的GammaCore標籤，擴大分銷渠道（包括在線渠道），以及在弗吉尼亞州每個設施內擴大影響力。
More details: electroCore IR
更多詳情： 電芯紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。